LifeStance Health Group, Inc. cash flow to debt ratio of 75.30% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.

LifeStance Health Group, Inc.'s free cash flow has increased 28.39% from $85.69M last year to $110.03M, signaling increasing performance

LifeStance Health Group, Inc.'s debt to equity ratio is 0.13, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

LifeStance Health Group, Inc.'s debt has decreased relative to shareholder equity from 0.34 last year to 0.13 today, signaling strengthened financials

LifeStance Health Group, Inc. has a net debt to EBITDA ratio of 0.00x, which is below the 3.00x threshold, indicating healthy leverage and financial stability

LifeStance Health Group, Inc.'s interest coverage ratio of 4.32 indicates that earnings with good margin can cover interest payments on company debt

LifeStance Health Group, Inc.'s profit margin has increased (-133.80%) in the last year from -4.59% to 1.55%, signaling increasing performance

LifeStance Health Group, Inc.'s short-term assets of $416.20M exceed its short-term liabilities of $251.96M

LifeStance Health Group, Inc.'s return on assets of 1.08% is lower than the 5.00% threshold, indicating inefficient asset utilization

LifeStance Health Group, Inc.'s return on equity of 1.56%, is lower than 15.00%, indicating bad performance

LifeStance Health Group, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation

LifeStance Health Group, Inc. had positive net income in only 1.00 out of 5 years, indicating unstable earnings

LifeStance Health Group, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures

LifeStance Health Group, Inc. has a free cash flow yield of 2.63%, which is above the 2.00% threshold, indicating strong cash generation relative to market value

LifeStance Health Group, Inc.'s yearly earnings has increased -116.82% since last year from $-57.44M to $9.66M, signaling increasing performance

LifeStance Health Group, Inc.'s yearly revenue has increased 13.85% since last year from $1.25G to $1.42G, signaling increasing performance

ROIC 1.58% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

LifeStance Health Group, Inc.'s 3-year revenue CAGR of 18.33% is positive, indicating growing revenue over the past 3 years

LifeStance Health Group, Inc. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

LifeStance Health Group, Inc. had positive ROE in only 1.00 out of 5 years, indicating inconsistent returns on equity

LifeStance Health Group, Inc. has insufficient data to evaluate this check.

LifeStance Health Group, Inc. has an earnings yield of 0.56%, which is below the 4.00% threshold, indicating the stock may be expensive relative to its earnings

LifeStance Health Group, Inc. is overvalued relative to its fair value price of 1.56 based on EBITDA multiple model

LifeStance Health Group, Inc. has an EV/EBITDA ratio of 52.43x, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

LifeStance Health Group, Inc. is overvalued relative to its fair value price of -12.63 based on Earnings Fair Value model

LifeStance Health Group, Inc. has a PEG-ratio under 1 which is considered undervalued

LifeStance Health Group, Inc. has a price-to-book ratio of 2.83x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

LifeStance Health Group, Inc. has a price-to-sales ratio of 2.80x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue